Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 17/20 | 0.43 |
| ▸ | CTRC | Q99895 | 10/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962194 | 0.91 | CMA1 (0.44) | CMA1CTRCCTSG | |
| SCHEMBL6752547 | 0.90 | ELANE (0.43) | ELANECMA1CTRC | |
| SCHEMBL7962409 | 0.88 | ELANE (0.45) | ELANECMA1CTRC | |
| SCHEMBL31419970 | 0.86 | CMA1 (0.44) | ELANECMA1CTRC | |
| SCHEMBL6710145 | 0.86 | ELANE (0.47) | ELANECMA1CTRC | |
| SCHEMBL4350497 | 0.86 | CMA1 (0.44) | ELANECMA1CTRC | |
| SCHEMBL7965669 | 0.85 | CMA1 (0.42) | CMA1CTRC | |
| SCHEMBL7962870 | 0.85 | CMA1 (0.44) | CMA1CTRC | |
| SCHEMBL7951070 | 0.85 | ELANE (0.43) | ELANECMA1CTRC | |
| SCHEMBL6706856 | 0.84 | CMA1 (0.58) | CMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | claimed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | INOUE JUN (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1224945-A1 | TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-24 | — | — | EP | disclosed |
| US-6271238-B1 | USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | CMA1, THOP1, TPSAB1 | ELANE 867/4885CMA1 1/4885CTRC 40/4885 |
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | CMA1, ACE, AGTR1 | ELANE 256/4885CMA1 1/4885CTRC 824/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | ELANE 2176/4885CMA1 313/4885CTRC 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.